ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers.

ABSTRACT: Advanced and metastatic estrogen receptor-positive (ER⁺ ) breast cancers are often endocrine resistant. However, endocrine therapy remains the primary treatment for all advanced ER⁺ breast cancers. Treatment options that may benefit resistant cancers, such as add-on drugs that target resistance pathways or switching to chemotherapy, are only available after progression on endocrine therapy. Here we developed an endocrine therapy prognostic model for early and advanced ER⁺ breast cancers. The endocrine resistance (ENDORSE) model is composed of two components, each based on the empirical cumulative distribution function of ranked expression of gene signatures. These signatures include a feature set associated with long-term survival outcomes on endocrine ther

SUBMITTER: Nath A 

PROVIDER: S-EPMC9172932 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature